Lobe Sciences (TSE:LOBE)
:LOBE
Want to see TSE:LOBE full AI Analyst Report?
Top Page
Lobe Sciences
(LOBE)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.08
▲(28.33% Upside)
Action:Reiterated
Date:06/20/26
The score is primarily driven down by weak financial performance (no revenue, persistent losses, and negative free cash flow indicating ongoing funding reliance). Technical indicators also lean bearish (negative MACD and price below key short-term moving averages). Valuation offers limited support because the company is loss-making (negative P/E) and there is no dividend yield data.
Positive Factors
Low Leverage in Latest Period
Modest reported debt (debt-to-equity ~0.19, ~$0.3M) reduces near-term solvency pressure and gives management some financial flexibility. Over a 2-6 month horizon this lowers immediate default risk and preserves options for staged financing or partnership deals to fund development milestones.
Negative Factors
No Revenue and Persistent Losses
The company is effectively pre-revenue with substantial recurring operating and net losses. This structural absence of top-line validation increases execution and financing risk, requiring continual capital to progress clinical programs and leaving unclear timing for sustainable revenue generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage in Latest Period
Modest reported debt (debt-to-equity ~0.19, ~$0.3M) reduces near-term solvency pressure and gives management some financial flexibility. Over a 2-6 month horizon this lowers immediate default risk and preserves options for staged financing or partnership deals to fund development milestones.
Read all positive factors
Lobe Sciences (LOBE) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$22.73M
Dividend YieldN/A
Average Volume (3M)19.65K
Price to Earnings (P/E)―
Beta (1Y)-0.11
Revenue GrowthN/A
EPS Growth13.41%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding284,102,500
10 Day Avg. Volume13,139
30 Day Avg. Volume19,648
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lobe Sciences Business Overview & Revenue Model
Company Description
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-ac...
How the Company Makes Money
null...
Lobe Sciences Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
28
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Nov 2025 | Nov 2024 | Aug 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 136.21K | 840.53K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 134.45K | 772.83K | -10.22K | 0.00 |
| EBITDA | -6.72M | -4.27M | -4.12M | -4.40M | -11.96M | -6.16M |
| Net Income | -5.62M | -4.43M | -4.42M | -4.71M | -12.25M | -22.82M |
Balance Sheet | ||||||
| Total Assets | 5.05M | 7.59M | 258.57K | 2.30M | 1.75M | 12.10M |
| Cash, Cash Equivalents and Short-Term Investments | 4.96M | 7.54M | 237.77K | 140.29K | 907.54K | 7.43M |
| Total Debt | 316.49K | 273.35K | 1.75M | 332.64K | 0.00 | 0.00 |
| Total Liabilities | 3.21M | 2.70M | 3.37M | 2.46M | 1.30M | 804.70K |
| Stockholders Equity | 304.45K | 2.36M | -3.11M | -160.13K | 445.69K | 11.29M |
Cash Flow | ||||||
| Free Cash Flow | -3.44M | -1.42M | -462.29K | -1.72M | -2.73M | -5.04M |
| Operating Cash Flow | -3.44M | -1.42M | -462.29K | -1.72M | -2.73M | -5.04M |
| Investing Cash Flow | -3.97M | 6.56M | 0.00 | 0.00 | 1.74M | 1.07M |
| Financing Cash Flow | 8.46M | 514.40K | 563.51K | 950.01K | 753.12K | 4.92M |
Lobe Sciences Technical Analysis
Negative
0.06
Price Trends
0.11
Negative
0.09
Negative
0.07
Positive
Market Momentum
>-0.01
Positive
35.36
Neutral
9.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LOBE, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.36 is Neutral, neither overbought nor oversold. The STOCH value of 9.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:LOBE.
Lobe Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | C$29.74M | -3.40 | -19.10% | ― | 0.66% | -14.29% | |
55 Neutral | C$8.50M | -5.33 | 11.57% | ― | -16.08% | -547.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$11.54M | -3.30 | ― | ― | -25.05% | 67.74% | |
42 Neutral | C$22.73M | -3.83 | ― | ― | ― | 13.41% | |
41 Neutral | C$16.35M | -4.31 | -68.32% | ― | 1.96% | -24.60% | |
41 Neutral | C$19.26M | -90.11 | -2.15% | ― | 24.10% | 94.52% |
* Healthcare Sector Average
TSE:LOBE
Lobe Sciences
0.08
0.05
128.57%
TSE:LABS
MediPharm Labs
0.07
>-0.01
-6.67%
TSE:PCLO
PharmaCielo
0.08
<0.01
10.29%
TSE:OILS
Nextleaf Solutions
0.05
-0.02
-28.57%
TSE:AVCN
Avicanna
0.13
-0.13
-50.00%
TSE:GWAY
Greenway Greenhouse Cannabis Corp.
0.15
-0.07
-30.95%
Lobe Sciences Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Lobe Sciences Launches $950,000 Non-Brokered Share Offering to Fund Operations
Positive
Apr 11, 2026
Lobe Sciences has launched a non-brokered private placement of 14,615,384 common shares at $0.065 per share, aiming to raise approximately $950,000 in gross proceeds. The company plans to direct the funds toward working capital and general corpora...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Lobe Sciences Strengthens Balance Sheet and Adopts Subsidiary Model to Cut Dilution
Positive
Mar 25, 2026
Lobe Sciences has sharply improved its financial position since August 2024, slashing liabilities by 81%, cutting outstanding warrants by about 70% and boosting cash reserves from under $0.3 million to nearly $6 million. Total assets and net worki...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.